Please login to the form below

Not currently logged in

Janssen Biotech signs $975m deal to buy into new oral cancer drug

US biopharmaceutical company Pharmacyclics could receive almost $1bn if all milestones are met

Janssen Biotech has bought into a new investigational cancer drug in a deal that could be worth almost $1bn to Pharmacyclis, the US biopharmaceutical company that discovered it.

Bruton tyrosine kinase inhibitor PCI-32765 is an oral drug that is currently in phase I and II trials for a range of B-cell malignancy disorders including chronic lymphocytic leukaemia and non-Hodgkin's lymphoma.

Both markets are expected to see strong growth over the next few years, with analysts at Research and Markets forecasting chronic lymphocytic leukaemia will be worth $2.2bn by 2020 and non-Hodgkin's lymphoma to reach $11.9 billion by 2017

PCI-32765 is also being developed for a number of other indications, including multiple myeloma, mantle cell lymphoma and diffuse large B-cell lymphoma.

William Hait, global therapeutic head of oncology for Janssen, said: "The agreement with Pharmacyclics is an opportunity to bring a new form of oral therapy to patients with B-cell malignancies. PCI-32765 is an innovative compound, with broad applicability and the potential to help a large number of patients with B-cell malignancies."

Pharmacyclics will receive up to $975m for the deal, including an upfront payment of $150m and further development and regulatory milestone payments worth up to $825m.

In return Janssen and Pharmacyclics will split profits equally and share development and commercialisation costs.

Each company will take the lead on development for specific indications, with development costs shared on a 40 per cent (Pharmacyclics) to 60 per cent (Janssen) basis.

PCI-32765 is a small molecule that works by inhibiting the Bruton's tyrosine kinase (Btk), an essential element of the B-cell antigen receptor (BCR) signalling pathway.

BCR signalling is a critical pathway required for tumour expansion and proliferation, and PCI-32765 exerts its anti-tumour function by blocking BCR signalling and thereby inducing cell death.

The companies will collaborate on the development of PCI-32765 for oncology and other indications but their agreement does not include the drug's potential use to treat inflammation or immune mediated conditions.

9th December 2011


Featured jobs

Subscribe to our email news alerts


Add my company
Bedrock Healthcare Communications

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...
figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...